Table 1.

Number of patients with normal and elevated serum IgG4 concentrations in IgG4-AID and IgG4-RLD.

	Normal IgG4 concentrations IgG4 <1.35 g/L Patients			Elevated IgG4 concentrations IgG4 ≥1.35 g/L Patients
Disease/Autoantibody status	Female	Male	Total	Female	Male	Total
Healthy controls	8 (100%)	3 (60%)	11 (84.62%)	0 (0%)	2 (40%)	2 (15.38%)
Neurometabolic controls	29 (96.67%)	20 (86.96%)	49 (92.45%)	1 (3.33%)	3 (13.04%)	4 (7.55%)
IgG4-RLD	8 (80%)	1 (11.11%)	9 (47.37%)	2 (20%)	8 (88.89%)	10 (52.63%)
IgG4-AID pooled	16 (94.12%)	26 (78.79%)	42 (84%)	1 (5.88%)	7 (21.21%)	8 (16%)
LGI1 Ab pos.	4 (100%)	8 (72.73%)	12 (80%)	0 (0%)	3 (27.27%)	3 (20%)
Caspr2 Ab pos.	1 (100%)	8 (100%)	9 (100%)	0 (0%)	0 (0%)	0 (0%)
NF155/pan-NF Ab pos.	0 (0%)	1 (33.33%)	1 (33.33%)	0 (0%)	2 (66.67%)	2 (66.67%)
CNTN1/Caspr1, CNTN1, Caspr1 Ab pos.	0 (0%)	6 (75%)	6 (75%)	0 (0%)	2 (25%)	2 (25%)
MuSK Ab pos.	11 (91.67%)	3 (100%)	14 (93.33%)	1 (8.33%)	0 (0%)	1 (6.67%)

Values indicate number of patients (female, male and total) per group (normal and elevated IgG4), percentages indicate percent of females, males or total of both groups (normal and elevated IgG4).

Ab, antibody; Caspr1, contactin-associated protein-like 1; Caspr2, contactin-associated protein-like 2; CNTN1, contactin 1; IgG4, immunoglobulin type G subclass 4; IgG4-AID, IgG4 autoimmune disease; IgG4-RLD, IgG4-related disease; LGI1, leucine-rich glioma inactivated protein- 1; MuSK, muscle-specific kinase; NF155, neurofascin 155; pan-NF Ab pos, positive for pan neurofascin antibodies; pos, positive.

Bold values indicate the percentage of elevated serum IgG4 concentration in IgG4-RLD and in IgG4-AID.